These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 22622260)

  • 1. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
    Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ
    Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
    Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
    Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.
    Tiseo M; Gelsomino F; Boggiani D; Bortesi B; Bartolotti M; Bozzetti C; Sammarelli G; Thai E; Ardizzoni A
    Lung Cancer; 2011 Feb; 71(2):241-3. PubMed ID: 21168933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
    Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
    Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
    Won JK; Keam B; Koh J; Cho HJ; Jeon YK; Kim TM; Lee SH; Lee DS; Kim DW; Chung DH
    Ann Oncol; 2015 Feb; 26(2):348-54. PubMed ID: 25403583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
    Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
    Chuang JC; Neal JW; Niu XM; Wakelee HA
    Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.
    Lee JK; Park HS; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS; Kim WH; Bang YJ
    Cancer; 2012 Jul; 118(14):3579-86. PubMed ID: 22086654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer.
    Azzato EM; Deshpande C; Aikawa V; Aggarwal C; Alley E; Jacobs B; Morrissette J; Daber R
    Anticancer Res; 2015 May; 35(5):3007-12. PubMed ID: 25964588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of low-level EGFR T790M mutation in lung cancer tissues.
    Oh JE; An CH; Yoo NJ; Lee SH
    APMIS; 2011 Jul; 119(7):403-11. PubMed ID: 21635547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
    Lee JO; Kim TM; Lee SH; Kim DW; Kim S; Jeon YK; Chung DH; Kim WH; Kim YT; Yang SC; Kim YW; Heo DS; Bang YJ
    J Thorac Oncol; 2011 Sep; 6(9):1474-80. PubMed ID: 21642865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized targeted therapy in advanced non-small cell lung cancer.
    Ma PC
    Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS56-60. PubMed ID: 22614968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer.
    Johung KL; Yao X; Li F; Yu JB; Gettinger SN; Goldberg S; Decker RH; Hess JA; Chiang VL; Contessa JN
    Clin Cancer Res; 2013 Oct; 19(19):5523-32. PubMed ID: 23897899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
    Wong KK
    Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
    Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; Mulloy R; Sharma SV; Brannigan BW; Mohapatra G; Settleman J; Haber DA
    Nat Genet; 2005 Dec; 37(12):1315-6. PubMed ID: 16258541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-small cell lung cancer patients with EML4-ALK fusion gene are insensitive to cytotoxic chemotherapy.
    Morodomi Y; Takenoyama M; Inamasu E; Toyozawa R; Kojo M; Toyokawa G; Shiraishi Y; Takenaka T; Hirai F; Yamaguchi M; Taguchi K; Seto T; Sugio K; Ichinose Y
    Anticancer Res; 2014 Jul; 34(7):3825-30. PubMed ID: 24982409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.